Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection

There is limited information available concerning the effect of thymalfasin (Tα1) as an adjuvant therapy in hepatocellular carcinoma (HCC) patient who received liver resection. The present study aimed to evaluate whether Tα1 can improve the prognosis of small HCC patients after liver resection. A to...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Chao, Peng, Wei, Li, Chuan, Wen, Tian-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406071/
https://www.ncbi.nlm.nih.gov/pubmed/28422855
http://dx.doi.org/10.1097/MD.0000000000006606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406071/
https://www.ncbi.nlm.nih.gov/pubmed/28422855
http://dx.doi.org/10.1097/MD.0000000000006606

Ejemplares similares